Medmen Opportunity Fund: Investing In Cannabis Innovation

MedMen is a cannabis management firm that launched a $100 million investment fund in 2016. The company is based in Culver City, California, and was founded in 2010. It offers turnkey services to license holders in the areas of cultivation, extraction, production, and retail operations. MedMen's Opportunity Fund has been one of the most successful cannabis industry investments to date, achieving gains of about C$33.5 million on a C$10 million investment. The fund targets strategic investments in supply-constrained, high-barrier markets and is diversified on an asset and geographic basis. It also owns a portion of MedMen's management company, which provides resources and operational oversight. MedMen has raised funding from various investors, including Cap-Meridian Ventures and Wicklow Capital, and has expanded its presence across key markets in the U.S. and Canada.

The fund's investment strategy

The MedMen Opportunity Fund is a private equity fund that combines an understanding of the fragmented regulatory environment with an institutional operating management platform. The fund pursues strategic investments in supply-constrained, high-barrier-to-entry markets and is diversified on both an asset and geographic basis.

The fund seeks to own a portion of MedMen's management company, which will serve as its captive operating partner. This provides the fund with unrivalled resources and operational oversight for its assets. With expertise in the cannabis industry, MedMen guides investors through the complexities of entering and succeeding in this rapidly growing industry.

MedMen Opportunity Fund I launched in June 2016 and raised $60 million in 9 months. The fund targeted a raise of $100 million but raised approximately $60 million from 81 investors, investing in seven different projects, mostly in California and Nevada. The fund closed in April 2018 due to a pending liquidity event.

A subsequent fund, MedMen Opportunity Fund II, launched in May 2017 and raised $75 million in approximately 6 months.

The fund's performance

The MedMen Opportunity Fund has demonstrated impressive financial performance and growth since its inception. In June 2016, MedMen launched its first private equity fund, raising $60 million in 9 months. This was followed by the launch of their second private equity fund in May 2017, which raised $75 million in approximately 6 months.

MedMen's investment strategy focuses on strategic investments in supply-constrained, high-barrier-to-entry markets, with a focus on diversification across assets and geographies. One notable investment was in MedReleaf, a Canadian licensed producer, where MedMen achieved realized and unrealized gains of about C$33.5 million on a C$10 million investment. This particular investment highlighted the fund's success, returning approximately 335% for its 81 investors in less than ten months.

MedMen's funds have attracted prominent investors, such as Wicklow Capital, an active private company investor, and Captor Capital, a firm with diverse holdings and interests. MedMen's ability to raise significant capital and generate substantial returns reflects its strong performance and position within the cannabis industry.

Despite its successes, MedMen has faced some challenges, including layoffs and closures of some operations in California, Chicago, and Las Vegas. However, the company continues to pursue strategic investments and partnerships, and its funds have been well-received by investors. MedMen's performance has also been recognised by industry experts, with MedMen CEO Adam Bierman attributing their success to their ability to bring "institutional business practices to the cannabis industry."

MedMen's business model

MedMen is a cannabis management firm that owns and operates licensed cannabis facilities in cultivation, manufacturing, and retail. The company was founded in 2010 and is headquartered in Culver City, California.

MedMen has raised significant funding for its expansion and operations. Its first private equity fund, MedMen Opportunity Fund I, launched in June 2016 and raised $60 million in 9 months. This was followed by MedMen Opportunity Fund II, which raised $75 million in approximately 6 months. The company has also received funding from investors such as Cap-Meridian Ventures and Captor Capital.

MedMen's management group and funds own or operate a portfolio of businesses, including dispensaries, growing facilities, and a manufacturing plant. The company has a presence in high-profile cannabis markets such as New York, Las Vegas, and Los Angeles. MedMen aims to dominate these markets and create a unique retail brand.

The company's business model has attracted investors with its focus on bringing institutional business practices to the cannabis industry. MedMen's CEO, Adam Bierman, has emphasised their role as industry leaders in this regard. The company's success in raising funds and its expansion plans demonstrate the potential for growth and profitability in the legal cannabis industry.

MedMen's track record

MedMen has a strong track record in the cannabis industry. The company was founded in 2010 and is headquartered in Culver City, California. It is a full-service management company serving North America's legal cannabis industry, offering comprehensive services to licensed cultivation, extraction, production, and retail operations.

MedMen has raised significant funding to build what has been described as "an Apple Store for pot products". The company raised $15 million in venture funding from Cap-Meridian Ventures in April 2016 and launched its first private equity fund, MedMen Opportunity Fund I, in June 2016, raising $60 million in 9 months. The fund targeted a raise of $100 million but raised approximately $60 million from 81 investors, investing in seven different projects in California, Nevada, and New York.

MedMen Opportunity Fund has achieved notable success with its investments. One of its most notable achievements was a $25 million gain in a MedReleaf investment. In 2016, the fund made a $10 million investment in Canadian licensed producer MedReleaf, which began trading on the Toronto Stock Exchange after its $100 million IPO. The fund booked a profit of C$1.44 million and unrealized gains from its holdings, resulting in a return of approximately 335% for its 81 investors in less than ten months.

MedMen has continued to build on its success with subsequent funds. The MedMen Opportunity Fund II, launched in May 2017, raised $75 million in approximately 6 months. The company also raised $38 million in a private placement that closed in February 2018, with Captor Capital accounting for $25 million of the total investment.

The risks of investing in MedMen

Financial Risk

MedMen has been experiencing significant financial losses, with losses increasing to $83 million in fiscal Q4 2019, despite revenues of $42 million. The company has limited financial breathing room, with a market cap of $683 million and only $33.7 million in cash on hand. MedMen's spending on non-value-adding expenses, such as excessive executive compensation, has contributed to its financial woes. The company has also faced challenges in raising capital due to its falling stock price, and its aggressive spending has led to shareholder dilution.

Management and Financing Problems

MedMen has gone through a high turnover of executives, including CFOs, COOs, and General Counsels. The company has also been accused of wasting shareholder money and engaging in questionable practices, such as paying unlicensed brokers to sell its stock and making lavish expenditures on luxury items for executives. These issues have led to lawsuits and negative publicity.

Regulatory and Legal Risk

As a cannabis retailer, MedMen operates in an industry with complex and restrictive regulations. Marijuana's federal status as a Class I drug in the US creates additional challenges and barriers to entry. MedMen has also faced legal issues, such as a lawsuit against the city of Miami due to zoning restrictions impacting its dispensary locations.

Competition and Market Risk

MedMen faces intense competition in the cannabis market, particularly from well-established companies like Trulieve Cannabis, which has captured a significant market share in Florida. The company's revenue growth has been slow compared to its competitors, and it may struggle to expand its operations due to limited licenses and high taxes in certain states, such as California.

Volatility and Penny Stock Risk

MedMen's stock has displayed above-average volatility, and as a penny stock, it carries additional risks. The company's financial distress and high debt levels could lead to further dilution for shareholders or even the possibility of shareholders losing their entire investment if MedMen is unable to fulfill its financial obligations.

Frequently asked questions